<DOC>
	<DOCNO>NCT00851318</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy certolizumab pegol add-on medication methotrexate long term Japanese RA patient transfer Study 275-08-001 ( NCT00791999 ) , evaluate effect different dose regimen safety efficacy certolizumab pegol American College Rheumatology 20 % ( ACR20 ) responder complete Study 275-08-001 .</brief_summary>
	<brief_title>Long-term Treatment Study Certolizumab Pegol ( CDP870 ) Add-on Medication Methotrexate Japanese Rheumatoid Arthritis ( RA ) Patients</brief_title>
	<detailed_description>This study initiate Otsuka Pharmaceutical Co. , Ltd transfer Astellas 12/04/2012 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects participate Study 27508001 meet criterion describe . Patients reach ACR20 , prematurely discontinue Study 27508001 Week 16 complete Study 27508001 Week 24 . Patients able receive treatment MTX , Week 52 . Patients experience important protocol deviation mention Study 27508001 . Patients receive live attenuate vaccine Study 27508001 ( Except influenza pneumococcal vaccine ) . Patients find tuberculosis chest Xray Study 27508001 . Patients required treatment infection two different time Study 27508001 Women pregnant , lactating , childbearing potential wish conceive study poststudy 3 month . Patients investigator decide inappropriate participation study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>